<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>3 Biotechs With Recent Intensive Insider Buying [Inovio Pharmaceuticals Inc, Enanta Pharmaceuticals Inc] - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

 <script type="text/javascript">
 window.qbaka || (function(a,c){a.__qbaka_eh=a.onerror;a.__qbaka_reports=[];a.onerror=function(){a.__qbaka_reports.push(arguments);if(a.__qbaka_eh)try{a.__qbaka_eh.apply(a,arguments)}catch(b){}};a.onerror.qbaka=1;a.qbaka={report:function(){a.__qbaka_reports.push([arguments, new Error()]);},customParams:{},set:function(a,b){qbaka.customParams[a]=b},exec:function(a){try{a()}catch(b){qbaka.reportException(b)}},reportException:function(){}};var b=c.createElement("script"),e=c.getElementsByTagName("script")[0],d=function(){e.parentNode.insertBefore(b,e)};b.type="text/javascript";b.async=!0;b.src="//cdn.qbaka.net/reporting.js";"[object Opera]"==a.opera?c.addEventListener("DOMContentLoaded",d):d();qbaka.key="697c30d6de0ec176f16bc61dacb2980d"})(window,document);qbaka.options={autoStacktrace:1,trackEvents:1};
 </script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Market Currents - Real-time stock market news updates' ,
  'http://seekingalpha.com/currents/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Market Currents - Real-time stock market news updates ;action-uri=http://seekingalpha.com/currents/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta property="fb:admins" content="100006791796236" />

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="3 Biotechs With Recent Intensive Insider Buying">
<meta name="twitter:description" content="The healthcare sector has been the best-performing group in one year performance with a gain of 23.0% for the period.
  (click to enlarge)
In this article, I will feature three biotech stocks that have seen ">
<meta name='twitter:image' content='http://static1.cdn-seekingalpha.com/images/users_profile/000/398/827/big_pic.png?1324765507'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Enanta Pharmaceuticals Inc (NASDAQ:ENTA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH): 3 Biotechs With Recent Intensive Insider Buying" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NASDAQ:ENTA, NASDAQ:TTPH, NYSEMKT:INO" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/1325231" /><meta name="original-source" content="http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying"><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="3 Biotechs With Recent Intensive Insider Buying" />
<meta property="og:description" content="The healthcare sector has been the best-performing group in one year performance with a gain of 23.0% for the period.(click to enlarge)In this article, I will feature three biotech stocks that have seen intensive insider buyi" />
<link rel="canonical" href="http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying" />
<script>
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
</script>

<link href="http://static3.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1386679599" media="screen" rel="stylesheet" type="text/css" /><link href="http://static3.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1386679600" media="screen" rel="stylesheet" type="text/css" /><link href="http://static2.cdn-seekingalpha.com/stylesheets/article_packaged.css?1386679600" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var siteon = false;</script>
<script type="text/javascript" src="/javascripts/siteon.js"></script>

<script type="text/javascript">
  var users_on_site='2,735,527';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/article/1325231-3-biotechs-with-recent-intensive-insider-buying';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script src="http://static1.cdn-seekingalpha.com/javascripts/common_packaged.js?1386679557" type="text/javascript"></script>
<script src="http://static2.cdn-seekingalpha.com/javascripts/common2_packaged.js?1386679560" type="text/javascript"></script><script src="http://static1.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1386679561" type="text/javascript"></script><script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}
</script>

<script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@sectors@';
  var article_sectors_themes = '@quick-picks-lists@us@healthcare@article@';
  var ratings_hash={};
  var ARTICLE_ID = 1325231;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "";
  var author_slug = "markus-aarnio";
  var pticker_for_ads = "enta";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  var sector_name = "Healthcare";
  var sector_slug = "healthcare";
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

  
</script>
<script>var mone_article_tags = "{enta,ino,ttph};;;{healthcare};;;{quick-picks-lists,us,investing-ideas,sa-exclusive};;;{markus-aarnio}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            iframeAd("728x90",'http://ad.doubleclick.net/adj/sek.investing-ideas/quick-picks-lists;sz=728x90;x=x;tile=1;d=investing-ideas;t=quick-picks-lists;aid=1325231;d=investing-ideas;d=sectors;t=quick-picks-lists;t=us;t=healthcare;t=article;z=3;a=markus-aarnio;cnt=7;cnt=2;cnt=23;ldr=insider-ownership;s=enta;s=ino;s=ttph;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/currents/all" sasource="headtabs">Market Currents</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_ideas'>
          <a href="http://seekingalpha.com/dashboard/investing_ideas" sasource="headtabs">Investing Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_income'>
          <a href="http://seekingalpha.com/dashboard/investing_income" sasource="headtabs">Dividends &amp; Income</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='etfs'>
          <a href="http://seekingalpha.com/dashboard/etfs" sasource="headtabs">ETFs</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='macro_view'>
          <a href="http://seekingalpha.com/dashboard/macro_view" sasource="headtabs">Macro View</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">&nbsp;</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">380,031</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>
<script>
  //ABTEST: half of users go to analysis page instead of 4 dashboards
  (function(){
    if (ABTest.identity%2==0){
      var rules = [["/dashboard/investing_ideas", "/analysis/investing-ideas/all"],
                   ["/dashboard/investing_income", "/analysis/investing-income/all"],
                   ["/dashboard/etfs", "/analysis/etf-portfolio-strategy/all"],
                   ["/dashboard/macro_view", "/analysis/macro-view/all"]];
      $$('#nav_container ul li a').each(function(el){
        for (var i=0;i<rules.length;i++) el.href = el.href.replace(rules[i][0],rules[i][1]);
      });
    }
  })();
</script>

  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before ">
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">3 Biotechs With Recent Intensive Insider Buying</span>
              </h1>
      <div id="article_info">
        
        <div class="article_info_pos">
          <span>Apr  7 2013, 07:19</span>
          <span id='title_article_comments'></span>
          <span id="page_position"></span>
          <span class="author_name_for_print">by: Markus Aarnio </span>
            <span  class='print_hide'>&nbsp;|&nbsp;</span>
                        <span class='print_hide'>includes: </span><span id='about_stocks'><a href="/symbol/enta" title='Enanta' sasource='article_about'>ENTA</a>, <a href="/symbol/ino" title='Inovio Pharmaceuticals, Inc.' sasource='article_about'>INO</a>, <a href="/symbol/ttph" title='Tetraphase Pharmaceuticals' sasource='article_about'>TTPH</a></span>       	</div>
        <div id="bookmark_top" class="bookmark_container">
  <div id="bookmark_title_top" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_top">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_top" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_top");
</script>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>
    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
          <p>The <a href="http://www.finviz.com/groups.ashx" target="_blank" rel="nofollow">healthcare sector</a> has been the best-performing group in one year performance with a gain of 23.0% for the period.</p><p><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-1365183346188057-Markus-Aarnio_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-1365183346188057-Markus-Aarnio.png" hspace="6" vspace="6" /></a></em></p><p>In this article, I will feature three biotech stocks that have seen <a href="http://www.dailyspeculations.com/scholarly/NiederInsider2.pdf" target="_blank" rel="nofollow">intensive insider buying</a> during the last 30 days. Intensive insider buying can be defined by the following three criteria:</p><ol><li>The stock is purchased by three or more insiders within one month.</li><li>The stock is sold by no insiders in the month of intensive purchasing.</li><li>At least two purchasers increased their holdings by more than 10%.</li></ol><p>1. <strong>Tetraphase Pharmaceuticals</strong> (<a href='http://seekingalpha.com/symbol/ttph' title='Tetraphase Pharmaceuticals'>TTPH</a>) is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.</p><p><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651828006288795-Markus-Aarnio_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651828006288795-Markus-Aarnio.png" hspace="6" vspace="6" /></a></em></p><p><strong>Insider buying by insider (last 30 days)</strong></p><ul><li>Cmea Ventures VI purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000118143113019231/xslF345X03/rrd374462.xml" target="_blank" rel="nofollow">642,857 shares</a> on March 25 pursuant to an <a href="http://ir.tphase.com/releasedetail.cfm?ReleaseID=749733" target="_blank" rel="nofollow">initial public offering</a>. Cmea Ventures VI LP currently holds 2,208,706 shares or 11.1% of Tetraphase.</li><li>Flagship Ventures purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000118143113019227/xslF345X03/rrd374240.xml" target="_blank" rel="nofollow">491,824 shares</a> on March 25 pursuant to an initial public offering. Flagship Ventures currently holds 1,839,748 shares or 9.3% of Tetraphase.</li><li>Mediphase purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000118143113019224/xslF345X03/rrd374232.xml" target="_blank" rel="nofollow">285,713 shares</a> on March 25 pursuant to an initial public offering. Mediphase currently holds 1,654,544 shares or 8.3% of Tetraphase.</li><li>Excel Medical Fund purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000118143113019223/xslF345X03/rrd374234.xml" target="_blank" rel="nofollow">496,121 shares</a> on March 25 pursuant to an initial public offering. Excel Medical Fund currently holds 1,468,505 shares or 7.4% of Tetraphase.</li><li>Skyline Venture Partners purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000118143113019221/xslF345X03/rrd374236.xml" target="_blank" rel="nofollow">681,012 shares</a> on March 25 pursuant to an initial public offering. Skyline Venture Partners currently holds 2,190,145 shares or 11.0% of Tetraphase.</li><li>Fmr LLC purchased <a href="http://www.sec.gov/Archives/edgar/data/1373707/000031506613003135/xslF345X03/primary_doc.xml" target="_blank" rel="nofollow">642,857 shares</a> on March 25 pursuant to an initial public offering. Fmr LLC currently holds 642,857 shares or 3.2% of Tetraphase.</li></ul><p><strong>Insider buying by calendar month</strong></p><p>Here is a table of Tetraphase's <a href="http://www.openinsider.com/search?q=ttph" target="_blank" rel="nofollow">insider trading activity</a> by calendar month.</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Month</td><td>Insider buying / shares</td><td>Insider selling / shares</td></tr><tr><td>March 2013</td><td>3,240,384</td><td>0</td></tr><tr><td>February 2013</td><td>0</td><td>0</td></tr><tr><td>January 2013</td><td>0</td><td>0</td></tr></tbody></table><p>Tetraphase had its IPO on March 20.</p><p><strong>Financials</strong></p><p>The company reported the <a href="http://ir.tphase.com/secfiling.cfm?filingID=1193125-13-117520&amp;CIK=1373707" target="_blank" rel="nofollow">full year 2012</a> financial results with the following highlights:</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Revenue</td><td>$7.6 million</td></tr><tr><td>Net loss</td><td>$15.1 million</td></tr><tr><td>Cash (pro forma)</td><td>$76.4 million</td></tr><tr><td>Debt (pro forma)</td><td>$11.5 million</td></tr><tr><td>Net tangible book value (pro forma)</td><td>$3.23 per share</td></tr></tbody></table><p><strong>Competition</strong></p><p>There are a variety of available therapies marketed for the treatment of multi-drug resistant infections that Tetraphase would expect would compete with eravacycline, including meropenem, which is marketed by <strong>AstraZeneca</strong> (<a href='http://seekingalpha.com/symbol/azn' title='AstraZeneca Group plc'>AZN</a>) as Merrem, imipenem/cilastatin, which is marketed by <strong>Merck</strong> (<a href='http://seekingalpha.com/symbol/mrk' title='Merck & Co Inc.'>MRK</a>) as Primaxin, tigecycline, which is marketed by <strong>Pfizer</strong> (<a href='http://seekingalpha.com/symbol/pfe' title='Pfizer Inc.'>PFE</a>) as Tygacil, levofloxacin, which is marketed by Ortho-McNeil and <strong>Johnson &amp; Johnson</strong> (<a href='http://seekingalpha.com/symbol/jnj' title='Johnson & Johnson'>JNJ</a>) as Levaquin, and piperacillin/tazobactam, which is marketed by Pfizer as Zosyn. Many of the available therapies are well-established and widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. If eravacycline is approved, it may be priced at a significant premium over other competitive products. This may make it difficult for eravacycline to compete with these products.</p><p>There are also a number of products in clinical development by third parties to treat multi-drug resistant infections, including ceftazidime/avibactam and ceftaroline/avibactam, which are being developed by AstraZeneca, and cefalozine/tazobactam, which is being developed by <strong>Cubist</strong> (<a href='http://seekingalpha.com/symbol/cbst' title='Cubist Pharmaceuticals, Inc.'>CBST</a>). If Tetraphase's competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than Tetraphase, it could result in Tetraphase's competitors establishing a strong market position before Tetraphase is able to enter the market.</p><p><strong>My analysis</strong></p><p>The stock started trading on March 20 after the initial public offering. There were six different insiders buying the shares and there were no insiders selling the shares at the IPO. All current executive officers and directors as a group own 54.1% of the company.</p><p>Tetraphase expects to conduct two global Phase 3 clinical trials of eravacycline, one for the treatment of complicated intra-abdominal infections and one for the treatment of complicated urinary tract infections. Tetraphase expects to have top-line data from both of these clinical trials in the first quarter of 2015. The stock could be a good pick for a long-term portfolio.</p><p>2. <strong>Enanta Pharmaceuticals</strong> (<a href='http://seekingalpha.com/symbol/enta' title='Enanta'>ENTA</a>) is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus [HCV]. These inhibitors include members of the direct acting antiviral [DAA] inhibitor classes - protease (partnered with <strong>AbbVie</strong> (<a href='http://seekingalpha.com/symbol/abbv' title='AbbVie Inc.'>ABBV</a>)), NS5A (partnered with <strong>Novartis</strong> (<a href='http://seekingalpha.com/symbol/nvs' title='Novartis AG'>NVS</a>)) and nucleotide polymerase as well as a host-targeted antiviral [HTA] inhibitor class targeted against cyclophilin.</p><p><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2013/4/1/398827-13648190813302464-Markus-Aarnio_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/4/1/398827-13648190813302464-Markus-Aarnio.jpg" hspace="6" vspace="6" /></a></em></p><p>Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.</p><p><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651825953404183-Markus-Aarnio_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651825953404183-Markus-Aarnio.png" hspace="6" vspace="6" /></a></em></p><p><strong>Insider buying by insider (last 30 days)</strong></p><ul><li>Gregory Verdine purchased <a href="http://www.sec.gov/Archives/edgar/data/1177648/000090866213000159/xslF345X03/edgar.xml" target="_blank" rel="nofollow">3,324 shares</a> on March 26 pursuant to an <a href="http://www.enanta.com/enanta-pharmaceuticals-announces-closing-of-initial-public-offering-and-exercise-of-underwriters-over-allotment-option/" target="_blank" rel="nofollow">intial public offering</a>. Gregory Verdine currently holds 3,324 shares or less than 0.1% of Enanta. Gregory Verdine is a co-founder of Enanta, and has served as a member of the board of directors since 1996.</li><li>TVM V Life Science Ventures purchased <a href="http://www.sec.gov/Archives/edgar/data/1177648/000101297513000125/xslF345X03/edgar.xml" target="_blank" rel="nofollow">132,949 shares</a> on March 26 pursuant to an intial public offering. TVM V Life Science Ventures currently holds 2,532,119 shares or 14.5% of Enanta.</li><li>Saints Capital Granite purchased <a href="http://www.sec.gov/Archives/edgar/data/1177648/000118143113019348/xslF345X03/rrd375058.xml" target="_blank" rel="nofollow">66,474 shares</a> on March 26 pursuant to an intial public offering. Saints Capital Granite currently holds 2,071,975 shares or 11.9% of Enanta.</li><li>Terry Vance purchased <a href="http://www.sec.gov/Archives/edgar/data/1177648/000090866213000160/xslF345X03/edgar.xml" target="_blank" rel="nofollow">13,295 shares</a> on March 26 pursuant to an intial public offering. Terry Vance currently holds 13,295 shares or less than 0.1% of Enanta. <a href="http://www.enanta.com/about-enanta/board-of-directors/" target="_blank" rel="nofollow">Terry Vance</a> has served as a member of the board of directors since June 2011.</li></ul><p><strong>Insider buying by calendar month</strong></p><p>Here is a table of Enanta's <a href="http://www.openinsider.com/search?q=enta" target="_blank" rel="nofollow">insider trading activity</a> by calendar month.</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Month</td><td>Insider buying / shares</td><td>Insider selling / shares</td></tr><tr><td>March 2013</td><td>216,042</td><td>0</td></tr><tr><td>February 2013</td><td>0</td><td>0</td></tr><tr><td>January 2013</td><td>0</td><td>0</td></tr></tbody></table><p>Enanta had its IPO on March 21.</p><p><strong>Financials</strong></p><p>The company reported the <a href="http://ir.enanta.com/phoenix.zhtml?c=147990&amp;p=irol-SECText&amp;TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTg4MTQwMDYmRFNFUT0wJlNFUT0wJlNRREVTQz1TRUNUSU9OX0VOVElSRSZzdWJzaWQ9NTc%3d" target="_blank" rel="nofollow">full year 2012</a> financial results with the following highlights:</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Revenue</td><td>$41.7 million</td></tr><tr><td>Net income</td><td>$1.4 million</td></tr><tr><td>Cash (pro forma)</td><td>$103.5 million</td></tr><tr><td>Net tangible book value (pro forma)</td><td>$6.79 per share</td></tr></tbody></table><p><strong>Competition</strong></p><p>Enanta expects its current and future product candidates to face intense and increasing competition as new products enter the HCV and antibacterial markets and advanced technologies become available, particularly in the case of HCV in combinations with existing products and other new products. Two drug products, Incivek (telaprevir) of <strong>Vertex</strong> (<a href='http://seekingalpha.com/symbol/vrtx' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) and Victrelis (boceprevir) of Merck, were approved in 2011 by the FDA for the treatment of HCV in combination with interferon and ribavirin, which in combination were the previous standard of care. These and other potential new treatment regimens may render Enanta's HCV product candidates noncompetitive. In particular, Enanta's HCV product candidates may not be able to compete successfully with other products in development in multiple classes of inhibitors of HCV, including protease inhibitors, polymerase inhibitors (nucleoside and non-nucleoside), NS5A inhibitors and cyclophilin inhibitors, under development by companies such as <strong>Achillion</strong> (<a href='http://seekingalpha.com/symbol/achn' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>), Astra-Zeneca, Boehringer Ingelheim, <strong>Bristol-Myers Squibb</strong> (<a href='http://seekingalpha.com/symbol/bmy' title='Bristol-Myers Squibb Company'>BMY</a>), <strong>Gilead</strong> (<a href='http://seekingalpha.com/symbol/gild' title='Gilead Sciences, Inc.'>GILD</a>), <strong>GlaxoSmithKline</strong> (<a href='http://seekingalpha.com/symbol/gsk' title='GlaxoSmithKline'>GSK</a>), <strong>Idenix</strong> (<a href='http://seekingalpha.com/symbol/idix' title='Idenix Pharmaceuticals, Inc.'>IDIX</a>), Johnson &amp; Johnson, <strong>Medivir</strong> (<a href='http://seekingalpha.com/symbol/mvrbf' title='Medivir ABB'>GM:MVRBF</a>), Merck, Pfizer, Presidio, <strong>Roche</strong> (<a href='http://seekingalpha.com/symbol/rhhby' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) and Vertex, as well as by Enanta's collaborators.</p><p>Enanta's MRSA program faces competition from other therapeutic products that address serious Gram-positive bacterial infections, such as Cubicin, marketed by Cubist; vancomycin, marketed generically by AbbVie, Shionogi and others; and Zyvox, marketed by Pfizer, as well as future competition from drug candidates currently in clinical development.</p><p><strong>My analysis</strong></p><p>The stock started trading on March 21 after the initial public offering. There were four different insiders buying the shares and there were no insiders selling the shares at the IPO. Enanta's executive officers and directors and stockholders who owned more than 5% of outstanding common stock before the IPO will, in the aggregate, beneficially own shares representing approximately 69.82% of outstanding capital stock.</p><p>Total worldwide sales of HCV therapies were over $3.5 billion in 2011. Enanta is eligible to receive over the next several years an aggregate of $430 million based on potential future pre-commercialization milestones under its AbbVie and Novartis collaborations. Enanta's only product candidate that has advanced beyond Phase 2 clinical trials is ABT-450. Phase 3 trials of ABT-450 in combination therapy started in October 2012, and the full registrational program was announced in November 2012. Enanta estimates that it will likely be at least two years before a New Drug Application for one of its collaborators' combination therapies could be approved by the FDA. The stock could be a good pick for a long-term portfolio.</p><p>3. <strong>Inovio Pharmaceuticals</strong> (<a href='http://seekingalpha.com/symbol/ino' title='Inovio Pharmaceuticals, Inc.'>INO</a>) engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases.</p><p><em>(click to enlarge)<a href="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651821792398868-Markus-Aarnio_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/4/5/398827-13651821792398868-Markus-Aarnio.png" hspace="6" vspace="6" /></a></em></p><p><strong>Insider buying by insider (last 30 days)</strong></p><ul><li>Angel Cabrera purchased <a href="http://www.sec.gov/Archives/edgar/data/1055726/000117911013005653/xslF345X03/edgar.xml" target="_blank" rel="nofollow">40,000 shares</a> on March 22 and currently holds 115,000 shares or less than 0.1% of the company. <a href="http://www.inovio.com/company/leadership/board-of-directors/" target="_blank" rel="nofollow">Angel Cabrera</a> serves as a director of the company.</li><li>Niranjan Sardesai purchased <a href="http://www.sec.gov/Archives/edgar/data/1055726/000117911013005633/xslF345X03/edgar.xml" target="_blank" rel="nofollow">25,000 shares</a> on March 20 and currently holds 101,800 shares or less than 0.1% of the company. <a href="http://www.inovio.com/company/leadership/management/" target="_blank" rel="nofollow">Niranjan Sardesai</a> was appointed Chief Operating Officer of Inovio in January 2012.</li><li>Joseph Kim purchased <a href="http://www.openinsider.com/insider/Kim-Jong-Joseph/1464549" target="_blank" rel="nofollow">150,000 shares</a> on March 20 - April 2 and currently holds 11,940,809 shares or 6.6% of the company. Joseph Kim was appointed President and CEO of Inovio Pharmaceuticals in June 2009.</li></ul><p><strong>Insider buying by calendar month</strong></p><p>Here is a table of Inovio's <a href="http://www.openinsider.com/search?q=ino" target="_blank" rel="nofollow">insider trading activity</a> by calendar month.</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Month</td><td>Insider buying / shares</td><td>Insider selling / shares</td></tr><tr><td>April 2013</td><td>90,000</td><td>0</td></tr><tr><td>March 2013</td><td>125,000</td><td>0</td></tr><tr><td>February 2013</td><td>0</td><td>0</td></tr><tr><td>January 2013</td><td>100,000</td><td>0</td></tr><tr><td>December 2012</td><td>0</td><td>25,000</td></tr><tr><td>November 2012</td><td>0</td><td>4,961,020</td></tr><tr><td>October 2012</td><td>0</td><td>922,524</td></tr><tr><td>September 2012</td><td>0</td><td>0</td></tr><tr><td>August 2012</td><td>75,000</td><td>0</td></tr><tr><td>July 2012</td><td>0</td><td>0</td></tr><tr><td>June 2012</td><td>65,000</td><td>0</td></tr><tr><td>May 2012</td><td>60,000</td><td>0</td></tr><tr><td>April 2012</td><td>0</td><td>0</td></tr><tr><td>March 2012</td><td>50,000</td><td>0</td></tr></tbody></table><p>The month of March 2013 has seen the most insider buying since March 2012.</p><p><strong>Financials</strong></p><p>The company reported the <a href="http://ir.inovio.com/2013-03-18-Inovio-Pharmaceuticals-Reports-2012-Fourth-Quarter-and-Year-End-Financial-Results" target="_blank" rel="nofollow">full year 2012</a> financial results on March 18 with the following highlights:</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Revenue</td><td>$4.1 million</td></tr><tr><td>Net loss</td><td>$19.7 million</td></tr><tr><td>Cash</td><td>$13.8 million</td></tr></tbody></table><p>Subsequent to year end, the company sold 8,222,966 shares of common stock under its ATM common stock sales agreement for net proceeds of $5.6 million.</p><p>On <a href="http://ir.inovio.com/2013-03-12-Inovio-Pharmaceuticals-Closes-15-1-Million-Offering-of-Common-Stock-and-Warrants" target="_blank" rel="nofollow">March 7, 2013</a>, Inovio closed an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase an aggregate of up to 13,688,633 shares of common stock. The net proceeds, after deducting the underwriters' discounts and other estimated offering expenses, and assuming no exercise of the warrants, were approximately $14.0 million.</p><p><strong>Outlook</strong></p><p>Inovio believes that current cash and cash equivalents plus short-term investments are sufficient to meet its planned working capital requirements through 2014.</p><p><strong>Competition</strong></p><p><a href="http://secfilings.com/searchresultswide.aspx?TabIndex=2&amp;FilingID=9168256&amp;companyid=1353&amp;ppu=%252fdefault.aspx%253fticker%253dINO%2526amp%253bauth%253d1" target="_blank" rel="nofollow">There are several</a> development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. These include Crucell N.V (now part of J&amp;J), <strong>Sanofi-Aventis</strong> (<a href='http://seekingalpha.com/symbol/sny' title='sanofi-aventis'>SNY</a>), Novartis, GlaxoSmithKline, Merck, Pfizer, and MedImmune, a wholly owned subsidiary of AstraZeneca.</p><p>In addition, a number of companies are developing products to address the same diseases that Inovio is targeting. For example, Sanofi-Aventis, Novartis, MedImmune, GlaxoSmithKline, CSL (in collaboration with Merck), and others have products or development programs for influenza. Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer; <strong>Advaxis</strong> (<a href='http://seekingalpha.com/symbol/adxs' title='Advaxis Inc.'>ADXS</a>) has a therapeutic cervical dysplasia/cancer product in Phase II trials. Much of the development for HIV and malaria vaccines is being done by government and non-government organizations such as the NIH and Bill &amp; Melinda Gates Foundation.</p><p>Inovio competes with companies that are developing DNA delivery technologies, such as viral delivery systems, lipid-based systems, or electroporation technology with an aim to carry out in vivo gene delivery for the treatment of various diseases. Currently there are five key DNA delivery technologies: viral, lipids, naked DNA, "gene gun" and electroporation. All of these technologies have shown promise, but they each also have their unique obstacles to overcome. Inovio believes its electroporation system is strongly positioned to succeed as the dominant delivery method for DNA-based vaccines.</p><p><strong>Upcoming milestones</strong></p><p>The company has the following <a href="http://www.inovio.com/assets/000/000/000/463.pdf" target="_blank" rel="nofollow">upcoming milestones</a> scheduled:<br></p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td><strong>Indication</strong></td><td><strong>Milestone</strong></td></tr><tr><td>Cervical Dysplasia (Therapeutic)</td><td>1Q/2014 Phase II study data</td></tr><tr><td>Leukemia (Therapeutic)</td><td>2013 Additional phase II data</td></tr><tr><td>HIV (Preventive/Therapeutic)</td><td>1H/2013 Publication of phase I data</td></tr><tr><td>Influenza (Preventive)</td><td>1H/2013 Phase I additional data</td></tr><tr><td>Malaria (Preventive)</td><td>2014 Start phase I/IIa</td></tr></tbody></table><p><strong>My analysis</strong></p><p>There have been three different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. There are seven <a href="http://www.streetinsider.com/rating_history.php?q=ino" target="_blank" rel="nofollow">analyst buy ratings</a>, zero neutral ratings and zero sell ratings with an average target price of $1.17.</p><p>On <a href="http://ir.inovio.com/2013-04-02-Inovio-Collaborator-ChronTech-Reports-Interim-Phase-II-Clinical-Study-Results-from-ChronVac-C-Vaccine-for-Hepatitis-C-Infection" target="_blank" rel="nofollow">April 2</a>, Inovio announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus [HCV] infection. The initial results did not show a statistically significant difference between treatment outcomes of the vaccinated and non-vaccinated groups. Despite these results, Joseph Kim, President and CEO of Inovio, purchased <a href="http://www.sec.gov/Archives/edgar/data/1055726/000117911013006143/xslF345X03/edgar.xml" target="_blank" rel="nofollow">90,000 shares</a> on April 2 after the data release.</p><p>Inovio has five pending catalysts for this and next year. I have a long position in the stock currently.</p>
            <div id="article_source">Source: <a href="/article/1325231-3-biotechs-with-recent-intensive-insider-buying?source=cc">3 Biotechs With Recent Intensive Insider Buying</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I am long <a href='http://seekingalpha.com/symbol/ino' title='Inovio Pharmaceuticals, Inc.'>INO</a>. <span id="additional_business_disclosure" style="display:none">I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</span> <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <script>SA.Pages.Article.handleDisclosures();</script>
        <div id="content_follow_up" class="underbar">
          <div id="follow_wrap">
              <div id="article_rta_bottom_container">
                <div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">&nbsp;</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>

<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      380,031
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="techpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id="techpromo_button" onclick="SA.Pages.Article.sendTechPromoMail()"></div>
</div>

<div id="ipadpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml90'>The #1 Portfolio App is Now on iPad!</div>
  <div id='sms_promo_line2' class='sms_line2 ml5 fwb mt10'>Get instant notifications & never miss a critical update on your stocks!</div>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt30"><div id="ipadpromo_button"></div></a>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt20"><div id="get_the_app"></div></a>
  <div id="ipadpromo_stars" class="fl mt15"></div>
</div>

<div id="store_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml25'>Which Seeking Alpha App is best for you?</div>
  <div class="mt15">
    <div class="ml25">
      <div class="fl"><input id="app_portfolio" type="checkbox"/></div>
      <div class="fl fwb ml10">Seeking Alpha Portfolio</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_tech" type="checkbox"/></div>
      <div class="fl fwb ml10">Tech Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_etf" type="checkbox"/></div>
      <div class="fl fwb ml10">ETF investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_energy" type="checkbox"/></div>
      <div class="fl fwb ml10">Energy Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="light-gray mt20 ml25">Email me a link to open from my phone:</div>
    <div class="ml25 mt5">
      <input id="email_to_download" type="text" style="width: 300px" class="fl" emailautofill="on" title="Email address" empty="Email address"/>
      <div class="bs-btn fl btn-primary ml10 btn-mini fwb" style="width: 70px;" onclick="SA.Pages.Article.sendLinkDownload()">Continue</div>
      <div class="cb"></div>
      <div class="red fs11" id="email_td_error"></div>
    </div>
  </div>
</div>

<div id="web_video_container" style="display:none" class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/LFNN6lhLtkk" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20" style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="ipad_video_container" style="display:none"  class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/zEnMPGkjOnI" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20"  style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="portfolio_unit" style="display:none">
  <div class="fwb fl mt3">PORTFOLIO</div>
<select id="portfolio_list" class="portfolio_list fl ml20" onchange="SA.Units.Portfolio.select(this)"></select>

<div class="cb"></div>

<table id="portfolio_table" class="portfolio_table fl mt20">
  <thead><tr><th class="symbol">Symbol</th><th class="tc">Alerts</th><th class="tr">Price</th><th class="tr">Chg</th><th class="tr">% Chg</th></tr></thead>
  <tbody></tbody>
</table>

<div class="cb"></div>

<div id="portfolio_stocks_container" class="fl mt20">
  <div style="float:left;position:relative">
    <input type="text" id="portfolio_stocks_input" class="add_stock_text" placeholder="example: GLD, GOOG" style="height: 18px;" />
  </div>
  <span id="portfolio_stocks_btn" class="portfolio_stocks_btn ml5" onclick="SA.Units.Portfolio.addStocks()">Add Stocks</span>
  <span id="portfolio_stocks_error" class="portfolio_stocks_error" style="display:none"></span>
</div></div>


              </div>
              <div id="article_rta_middle_container" style="display:none">
                <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         &nbsp;
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">380,031</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

              </div>
     		    <div id="article_tags" style="display:none">
              <div itemprop="articleSection" class="tagged_with">
                <span class="tagged_with_label">Tagged: </span><a href='/dashboard/investing_ideas' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/quick-picks-lists' sasource='article_navigation'>Quick Picks &amp; Lists</a>, <a href='/analysis/sectors/healthcare' sasource='article_navigation'>Healthcare</a>
              </div>
	          </div>
            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this article with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',1325231,'http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="3 Biotechs With Recent Intensive Insider Buying http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying?source=tweet $ENTA $INO $TTPH" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying?source=share" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div onclick="alert('click')">
      <div id="span_fb_widget_share" style="display: none; background: ur('/images/facebook_small.gif');" class="fb-share-button fl ml-10 mt1" data-href="http://seekingalpha.com/article/1325231-3-biotechs-with-recent-intensive-insider-buying?source=fb_share" data-type="button_count"></div>
    </div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'20px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '1325231'
        }
      });
    });

  </script>









  </script>
  </li>
</ul>            </div>
            <div class="bookmark_bottom_wrapper"><div id="bookmark_bottom" class="bookmark_container">
  <div id="bookmark_title_bottom" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_bottom">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_bottom" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_bottom");
</script></div>
	          <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="more_by_auth" class="more_by_auth"></div>
            <div id="more_by_ticker" class="article_bottom_units"></div>
            <div id="temporary_place_holder" class="mt10"></div>
            <div class="cleaner"></div>
          </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
      <div id="secondary_ads" class="no_big_gaps_secondary_ads" style="float:right;">
        <div id="author_avatar">
    <div class="follow_sidebar">
      <script>var author_info_popup_timeout;</script>
<div id="author_info"> 
  <div class="author_page_tools" id="author_image_header">
    <div class="author_info_wrap">
      <a href="/author/markus-aarnio" class='this_is_a_author_pic' sasource="about_lpic"><img class="this_is_a_author_pic_img" align="center" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/398/827/big_pic.png?1324765507" width="115" height="115" alt="Markus Aarnio picture" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();" /></a>
 <div id="goto_edit_picture" class="goto_edit_picture" style='display:none'><span onclick="return goto_update_picture();" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();"></span></div>
        <div id="article_author_info" style="display:none;" onmouseover="clearAuthorInfoPopupTimeout();" onmouseout="HideAuthorInfo();">
          <div>
            <div class="followup_contributor_info">
  <div class="followup_contributor_info_title">
    <span>About the author: </span>
    <a href="/author/markus-aarnio" sasource="about_name">Markus Aarnio</a>
  </div>

  <div class="followup_contributor_info_on_author">
    <div class="followup_contributor_info_pic_cont">
      <div class="pic_cont">
        <div class="pic_contributor">
          <div class="the_pic">
              <a href="/author/markus-aarnio" sasource="about_pic"><img align="center" width="54" height="54" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/398/827/big_pic.png?1324765507" alt="Markus Aarnio picture"/></a>
          </div>
        </div>
      </div>
    </div>
    <div class="followup_contributor_info_text">
      I have 15 years of investing experience. I have traded stocks, commodities and forex markets.
    </div>
    <div class="cleaner"></div>
	</div>
  <div class="followup_contributor_info_bottom_cnt">
    
    <div class="left_cnt">
      
    </div>
  </div>

  <div class="cleaner"></div>
</div>
<div class="followup_contributor_info_on_author_bottom"></div>

          </div>
        </div>
    </div>
    <a href="/author/markus-aarnio" itemprop="author" class="author_info_name" sasource="about_lname">Markus Aarnio</a>
    <div class="cleaner"></div>
      <span class="leaders_link">
        <div class="author_info_opinion_leader">
          <ul class="opinion_leader_list">
              <li class="lead_top_num1"><div class="content">on <a href="/analysis/investing-ideas/insider-ownership" sasource="author_id">Insider Ownership</a></div></li>
          </ul>
        </div>
      </span>
    <div class="author_info_nav_border">
      <div class="author_info_nav">
        <ul class="the_author_info_nav">
          <li><a href='/author/markus-aarnio/articles'>Articles <span>(730)</span></a></li>
            <li>
                   <a href='/author/markus-aarnio/instablog'>Instablog
                     <span>(1)</span>
                   </a>
                 </li>                        <li>
                   <a href='/author/markus-aarnio/comments'>Comments <span>(2,374)</span></a>
                 </li>              <script>if (/stats viewer/.test(readCookie("user_perm"))) document.write("<li><a href='/account/authorboard/earnings?for_user_id=398827'>Earnings</a></li>");</script>
          <li><a href='/author/markus-aarnio'>Profile</a></li>        </ul>
      </div>
    </div>
    <div class="cleaner"></div>
    <div class="user_followers_following">
      <div class="user_followers">
        <a href="/author/markus-aarnio/followers">
          <span id="followers" class="number followers_number_398827 followers_number_markus-aarnio">2,988</span>
          <span class="text">Followers</span>
        </a>
      </div>
      <div class="user_followers">
        <a href="/author/markus-aarnio/following">
          <span id="followings" class="number">206</span>
          <span class="text">Following</span>
        </a>
      </div>
    </div>

    <div id="follow_this_user" class="follow_this_user"></div>
    <script>Follow.author_sidebar__follow_button_initiator('markus-aarnio')</script>
    <span class='author_info_send_message' onclick='Messaging.sendMessage("537vqd4t", "Article Author ID Card Upper")'>Send Message</span>
    <div class="cleaner"></div>
  </div>
  <div class="follow_popup_wrapper">
      <div class="green_pop_wrapper" id="stop_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('stop_follow').style.display='none'"></span><p><span id="stop_follow_message"></span> Markus Aarnio</p><span class="stop_following" onclick="Follow.ajax_stop_follow_this_author(this, 'markus-aarnio')">Stop Following</span></div></div><div class="green_pop_wrapper" id="no_longer_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('no_longer_follow').style.display='none'"></span><p><span id="no_longer_message"></span> Markus Aarnio</p></div></div>  </div>
</div>
  <script>SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),35842)})</script>

    </div>
    <div class="cleaner"></div>
    
    </div>
          <div class="stickyad_wrapper">
            <div class="item banner160x600" id="fixed_banner160x600">
            </div>
          </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/quick-picks-lists;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=quick-picks-lists;aid=1325231;d=investing-ideas;d=sectors;t=quick-picks-lists;t=us;t=healthcare;t=article;z=3;a=markus-aarnio;cnt=7;cnt=2;cnt=23;ldr=insider-ownership;s=enta;s=ino;s=ttph;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
      <div class="item banner300x600">
        <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/quick-picks-lists;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=quick-picks-lists;aid=1325231;d=investing-ideas;d=sectors;t=quick-picks-lists;t=us;t=healthcare;t=article;z=3;a=markus-aarnio;cnt=7;cnt=2;cnt=23;ldr=insider-ownership;s=enta;s=ino;s=ttph;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
      </div>
        <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
    <script type="text/javascript">
      ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
    </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "ENTA";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


      

        <div id="article_sidebar" class="article_sidebar">
          <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
        </div>

        <div class="cleaner"></div>
        <div class="stickyad_wrapper">
          <div class="item banner300x250" id="article_dart_sticky"></div>
        </div>
      <script>
          SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/quick-picks-lists;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=quick-picks-lists;aid=1325231;d=investing-ideas;d=sectors;t=quick-picks-lists;t=us;t=healthcare;t=article;z=3;a=markus-aarnio;cnt=7;cnt=2;cnt=23;ldr=insider-ownership;s=enta;s=ino;s=ttph;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
      </script>
  </div>
  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/sejz" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2013 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
      
    </div>
   
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    Event.observe(window, 'scroll', check_positions);

    NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
    SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/quick-picks-lists;sz=160x600;x=x;tile=3;d=investing-ideas;t=quick-picks-lists;aid=1325231;d=investing-ideas;d=sectors;t=quick-picks-lists;t=us;t=healthcare;t=article;z=3;a=markus-aarnio;cnt=7;cnt=2;cnt=23;ldr=insider-ownership;s=enta;s=ino;s=ttph;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>
<script>
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})}
    SA.Pages.Article.primary = "";
    SA.Pages.Article.init({proSidebar: null});
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }
      
    if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);}
    var pagination_version = ABTest.identity%10;

    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      SA.Pages.Article.btb();

  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){ 
      SA.Pages.Article.articlePromo({"allSlugs":["enta","ino","ttph"],"primarySlug":null,"dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
</script>
    <script src="http://static3.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1386679573" type="text/javascript"></script>
<link href="http://static1.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1386679600" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static1.cdn-seekingalpha.com/javascripts/sa.js?1386679545");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static.cdn-seekingalpha.com/javascripts/tops.js?1386678500");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css?t=1386712432')});

  if (SA && SA.Data && SA.Data.User && SA.Data.User.loggedIn() && SA.Data.User.email() && SA.Data.User.email().match(/@seekingalpha.com/)){
    try{$('user_settings_pop').children[0].insert("<li class='mt10'><a href='javascript:void(0)' onclick='switch_status()'>PRO ON / OFF</a></li>");}catch(e){}
  }

  function switch_status(){
    new Ajax.Request('/authentication/get_menu', {
      asynchronous:true,
      method:'get',
      onComplete: function(transport) {
        eval(transport.responseJSON.code);
      }
    });
  }

  try{
      if (!siteon){
        $('header').outerHTML += '<div id="outage_message">Most of Seeking Alpha is currently unavailable due to scheduled maintenance. Most published articles are still available for viewing. We apologize for any inconvenience.</div>';
        $('user_settings_wrapper').hide();
        $('outage_message').style.top = document.viewport.getDimensions().height -48 + "px";
      }
  } catch(e){}
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static2.cdn-seekingalpha.com/javascripts/footer_packaged.js?1386679570" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?144';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?148';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>

<script type="text/javascript">if (typeof NREUMQ !== "undefined") { if (!NREUMQ.f) { NREUMQ.f=function() {
NREUMQ.push(["load",new Date().getTime()]);
var e=document.createElement("script");
e.type="text/javascript";
e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" +
  "js-agent.newrelic.com/nr-100.js";
document.body.appendChild(e);
if(NREUMQ.a)NREUMQ.a();
};
NREUMQ.a=window.onload;window.onload=NREUMQ.f;
};
NREUMQ.push(["nrfj","beacon-5.newrelic.com","c0370b1d43","334927,334964","cldeEUAJWgldEBsASkVRUwlXFRkWUA1D",0,53,new Date().getTime(),"","","","",""]);}</script>
    <div class="cleaner"></div>
  </body>
</html>
